Geneuro received a European patent for GNK-301, an antibody targeting K Env, with Phase 1 trials planned for the second half of 2027.

It’s a schtick we repeat whenever he needs to reorder something he buys in bulk, like gauze pads, deodorant, or gloves. He always feigns disappointment when we run out of something. “So irritating,” ...

Mindy Henderson has spent much of her life challenging the limits others have placed on her. When she was diagnosed with ...

Five Canadian college students personally affected by ALS were named recipients of the Kevin Daly Bursary, an award for their ALS advocacy. Financial programs like student bursaries help alleviate ...

In 1980, a local hospital hired me to launch their brand-new wellness department. I knew it would be an uphill battle. Back ...

Paradromics’ investigational Connexus brain-computer interface (BCI) enabled a woman with a progressive motor neuron disease to generate her own words in real time, answer open-ended questions, and ...

Filmmaker and University of Virginia graduate Chris Farina had the idea for a documentary about death and dying about 10 ...

The ALS Nexus 2026 conference highlighted cutting-edge research, experimental therapies, and advances in care for ALS.

Requests for a medically assisted death in ALS appear to be tied to individual preferences rather than disease severity, a ...

Many well-intentioned people romanticize caregiving, perhaps out of compassion or even admiration of one person caring for ...

An emerging body of evidence has hinted that ALS survival may be influenced by exposure to toxins or pollutants in the environment. Specifically, a handful of prior studies have found that ALS ...

Enrollment is complete in a Phase 2b trial of PHENOGENE-1A for mild-to-moderate ALS. ALS is a progressive disorder in which motor neurons die, with nervous system inflammation thought to play a role.